TIGIT Emerges as Key Target in Cancer Immunotherapy
How TIGIT Differs from First-Generation Therapies
A groundbreaking review published on September 22, 2025, identifies TIGIT as a critical next-generation immunotherapy target. The study, led by researchers in China, addresses persistent challenges in cancer treatment, including drug resistance and poor patient responses to existing therapies.
Malignant tumors continue to claim millions of lives annually. Conventional treatments like chemotherapy and first-generation immune checkpoint inhibitors (ICIs) often fail due to limited efficacy and resistance. The review, published by the Chinese Medical Journals Publishing House, proposes TIGIT—a protein that suppresses immune activity—as a novel target to overcome these barriers.
Unlike earlier ICIs that block PD-1 or CTLA-4 pathways, TIGIT operates through a distinct mechanism. By inhibiting TIGIT, immune cells regain their ability to attack tumors more effectively. Early trials suggest this approach could enhance response rates in patients who previously failed standard treatments. Researchers highlight its potential to synergize with existing therapies, creating combination regimens that tackle resistance.
What Evidence Supports TIGIT’s Potential?
The review analyzes preclinical and clinical data, showing TIGIT inhibition boosts T-cell activation in solid tumors. In trials involving lung and colorectal cancers, patients treated with TIGIT-targeted therapies demonstrated improved progression-free survival compared to conventional ICIs. However, challenges remain, including managing immune-related side effects and identifying biomarkers to predict patient suitability.
The study compiles findings from over 50 preclinical studies and 12 human trials. Data reveals that blocking TIGIT increases tumor infiltration by immune cells, a key factor in treatment success. Notably, 40% of participants in early-phase trials showed partial or complete remission, outperforming historical averages for first-generation ICIs.
Despite optimism, researchers caution that larger, randomized trials are needed. Safety profiles are still under investigation, with some cases of autoimmune flare-ups reported. Experts stress the importance of personalized treatment strategies to maximize benefits while minimizing risks.
Frequently Asked Questions
How does TIGIT inhibition work? TIGIT suppresses immune cell activity by binding to its ligand. Blocking this interaction reactivates T-cells to attack cancer cells more aggressively.
Are TIGIT therapies available yet? Most treatments are in early clinical trials. Regulatory approval is not expected until 2030, pending further research.
What are the main risks? Immune-related adverse events, such as colitis or hepatitis, have been observed. Ongoing studies aim to refine dosing to reduce toxicity.